

BAXTER INTERNATIONAL INC.
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

	Q2 2011			Q2 2010			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
BioScience									
Recombinants	\$239	\$331	\$570	\$233	\$292	\$525	3%	13%	9%
Plasma Proteins	103	260	363	110	204	314	(6%)	27%	16%
Antibody Therapy	261	120	381	211	99	310	24%	21%	23%
Regenerative Medicine	78	69	147	76	57	133	3%	21%	11%
Other ¹	6	86	92	6	70	76	0%	23%	21%
Total BioScience	\$687	\$866	\$1,553	\$636	\$722	\$1,358	8%	20%	14%
Medical Products²									
Renal	\$97	\$536	\$633	\$98	\$487	\$585	(1%)	10%	8%
Global Injectables	255	251	506	263	209	472	(3%)	20%	7%
IV Therapies	144	308	452	134	284	418	7%	8%	8%
Infusion Systems	137	96	233	132	84	216	4%	14%	8%
Anesthesia	88	55	143	84	46	130	5%	20%	10%
Other 1		5	6	(1)	4	3	N/M	25%	100%
Total Medical Products	\$722	\$1,251	\$1,973	\$710	\$1,114	\$1,824	2%	12%	8%
Transfusion Therapies³	\$9	\$1	\$10	\$9	\$3	\$12	0%	(67%)	(17%)
Total Baxter	\$1,418	\$2,118	\$3,536	\$1,355	\$1,839	\$3,194	5%	15%	11%

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.